The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | Should TP53 mutations be used to guide treatment decisions in Waldenström’s macroglobulinemia?
Shirley D’Sa, MD, FRCP, FRCPath, University College London, London, United Kingdom, discusses whether the presence of TP53 mutations should be used to guide treatment decisions for Waldenström’s macroglobulinemia. Dr D’Sa discusses her view that we are not quite ready to use TP53 mutations to guide treatment decisions, although she emphasizes its value as a prognostic marker. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
